We have previously detailed our clinical results using a TLR-4-activated dendritic cell vaccine to engender an antigen-specific immune response and prevent recurrence of HER-2/neu-positive ductal carcinoma in situ [13]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.